Evidence map›Paper›PMID 42422740›Full record

ArticleFrontiers in microbiology2026

Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against

Sakshi V Khairnar, Anna Sommers, Elena Muldiiarova, Kenneth W Bayles, David Oupický, Vinai C Thomas, Marat R Sadykov, Svetlana Romanova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sakshi V KhairnarCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
Anna SommersDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.
Elena MuldiiarovaDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.
Kenneth W BaylesDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.
David OupickýCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
Vinai C ThomasDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.
Marat R SadykovDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.
Svetlana RomanovaCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The escalating prevalence of antibiotic resistance represents a critical threat to global public health, while the development of new antibiotics remains limited. Vancomycin, a glycopeptide antibiotic, is essential for treating severe Gram-positive infections. However, the emergence of vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA)

Indexed as

antibiotic resistanceantimicrobial agentsglycopeptide antibioticssilver nanoparticlesStaphylococcus aureusvancomycin

Identifiers

PMID42422740
PMCPMC13342177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.